CNS drugmaker teams with CDMO on ALS mAb candidate

By Fiona BARRY contact

- Last updated on GMT

The mAbs has been approved to begin clinical trials
The mAbs has been approved to begin clinical trials

Related tags: Biotechnology

CDMO (contract development and manufacturing organisation) Goodwin Biotechnology is working with CNS biotech Q Therapeutics to produce mAbs for a clinical trial to treat motor neuron disease.

The partnership targets Q Therapeutics’ biopharma candidate – named Q-Cells – which has received an Investigational New Drug Application from the FDA for the treatment of motor neuron disease (also known as Amyotrophic Lateral Sclerosis (ALS) and Lou Gehrig’s disease). 

Goodwin Biotechnology has so far completed process development, scale-up, and cGMP manufacturing of Immunoglobulin M (IgM), the antibody used to isolate Q-Cells, as well as IgM’s ligand conjugate. IgM is a basic antibody produced by B cells; the largest in the human body. 

Q-Cells are glial-restricted progenitor cells (GRPs) – early descendants of neural stem cells that produce only ‘glia’ – which make up 50 per cent of cells in the brain, and are essential for supporting, maintaining and even restoring neuron health,​” said Deborah Eppstein, CEO, Q Therapeutics. 

Bioconjugation​ 

Goodwin Biotechnology specialises in bioprocess development and GMP manufacturing of biopharmaceuticals using mammalian cell lines and bioconjugation – bonding mAbs and recombinant proteins to other molecules. 

Muctarr Sesay, Chief Scientific Officer, Goodwin, said the technical team had overcome “potential aggregation, stability, formulation, bioconjugation, and purification issues associated with a hybridoma IgM monoclonal antibody.​” Goodwin’s regulatory division also prepared the antibody portion of Q Therapeutics’ CMC (Chemical Manufacturing and Controls) section of its IND submission, he added. 

Phase I-IIa trials of Q Cells are set to begin soon. 

This important milestone is a testament to the commitment and dedication of all of our scientific co-workers and supporters, that include the National Institute of Neurological Disorders and Stroke Translational Research Program (U01-NS06713) at the National Institutes of Health, the Maryland Stem Cell Research Fund, Bosarge Life Sciences, Nicholas Maragakis, MD, at Johns Hopkins University, MPI Research, Inc., the Biologics Consulting Group, and the Cell Therapy and Regenerative Medicine Facility (CTRM) at the University of Utah,​” said Deborah Eppstein.

Related news

Show more

Related products

show more

High quality excipients and formulation support

High quality excipients and formulation support

Roquette Pharma Solutions | 09-Nov-2021 | Product Brochure

As the world grapples with the effects of ongoing health crises, the market is expanding quickly as developers shift their focus to proactive therapeutics....

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars